<DOC>
	<DOCNO>NCT02745223</DOCNO>
	<brief_summary>A study establish safety , tolerability , efficacy PresbiDrops ( CSF-1 ) presbyopic subject .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy PresbiDrops ( CSF-1 ) , Topical Ophthalmic Drug Presbyopia</brief_title>
	<detailed_description />
	<mesh_term>Presbyopia</mesh_term>
	<criteria>1 . Men woman 40 65 year age ( inclusive ) . 2 . Subjects provide write informed consent participate study . 3 . Subjects sign presbyopia upon ophthalmic examination . 4 . Subjects normal presbyopia low distance refraction ( sphere great ±0.75 diopter cylinder great ±0.75 diopter cylinder [ DC ] , refraction along principal meridian great 1.00 diopter ) . 5 . Subjects must best correct vision 20/20 eye , currently depend read glass bifocals near addition &gt; +1.00 diopter . 6 . Subjects general good health opinion Investigator determine medical history . 7 . Women childbearing potential must negative urine pregnancy test Screening willing able use medically acceptable method birth control must postmenopausal . Acceptable method birth control study include : Vasectomy , tubal ligation , consistent use approve oral contraceptive ( birth control pill ) , intrauterine device ( IUD ) , hormonal implant , contraceptive injection double barrier method ( diaphragm spermicidal gel condom contraceptive foam ) . Postmenopausal woman define woman menstruation cessation 12 consecutive month prior sign inform consent form . 8 . Subjects must able understand requirement study must willing comply requirement study . 1 . History macular disease ocular condition congenital malformation . 2 . Any medical condition know affect structure uvea , cornea , lens , retina main function eye . 3 . No cataract minimal nuclear sclerosis . 4 . Severe dry eye . 5 . Any topical ophthalmic medication , artificial tear ( maximum 4 time per day ) medication associate fluctuation accommodative capacity and/or pupil size , unless stable dose least 3 month Screening visit . 6 . Contact lenses past three month Screening visit . 7 . A difference 0.50 diopter manifest spherical equivalent wave front refraction spherical equivalent . 8 . Pupil size le 2,5 mm either eye prior dilation ambient light 815 lux prior Baseline visit . 9 . A history herpes ( kind ) either eye . 10 . Cataract surgery and/or refractive surgery either eye . 11 . Known contraindication , hypersensitivity , and/or allergy study drug excipients . 12 . Any acute illness ( eg , acute infection ) within 48 hour first study drug administration , consider significance Investigator . 13 . Participation another clinical trial drug receive within 30 day Screening . 14 . Pregnant currently lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>